ATE544072T1 - Verwendung von bnp-typ-peptiden zur stratifizierung einer therapie mit erythropoetischen stimulierungsmitteln - Google Patents

Verwendung von bnp-typ-peptiden zur stratifizierung einer therapie mit erythropoetischen stimulierungsmitteln

Info

Publication number: ATE544072T1
Authority: AT; Austria
Prior art keywords: bnp; risk; esa; cardiovascular complication; type peptide
Prior art date: 2006-08-17

Application number

AT07788437T

Other languages

English (en)

Inventor

Zalan Ildiko Amann

Joachim Moecks

Hans Ulrich Burger

Cesar Escrig

Armin Scherhag

Frank Dougherty

Zuzana Herrmann

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-17

Filing date

2007-08-15

Publication date

2012-02-15

2007-08-15 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE544072T1 publication Critical patent/ATE544072T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
102000004196 processed proteins & peptides Human genes 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
239000003173 antianemic agent Substances 0.000 abstract 5
229940125367 erythropoiesis stimulating agent Drugs 0.000 abstract 5
101800000407 Brain natriuretic peptide 32 Proteins 0.000 abstract 3
102400000667 Brain natriuretic peptide 32 Human genes 0.000 abstract 3
101800002247 Brain natriuretic peptide 45 Proteins 0.000 abstract 3
230000002526 effect on cardiovascular system Effects 0.000 abstract 3
HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 abstract 3
229940079593 drug Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
102000003951 Erythropoietin Human genes 0.000 abstract 1
108090000394 Erythropoietin Proteins 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
102400001263 NT-proBNP Human genes 0.000 abstract 1
208000007502 anemia Diseases 0.000 abstract 1
230000002490 cerebral effect Effects 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
229940105423 erythropoietin Drugs 0.000 abstract 1
230000000302 ischemic effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
210000004898 n-terminal fragment Anatomy 0.000 abstract 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 abstract 1
230000001052 transient effect Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Pathology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT07788437T 2006-08-17 2007-08-15 Verwendung von bnp-typ-peptiden zur stratifizierung einer therapie mit erythropoetischen stimulierungsmitteln ATE544072T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11/465,191 US20080050749A1 (en)	2006-08-17	2006-08-17	Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
PCT/EP2007/058458 WO2008020043A1 (en)	2006-08-17	2007-08-15	The use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents

Publications (1)

Publication Number	Publication Date
ATE544072T1 true ATE544072T1 (de)	2012-02-15

Family

ID=38829610

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07788437T ATE544072T1 (de)	2006-08-17	2007-08-15	Verwendung von bnp-typ-peptiden zur stratifizierung einer therapie mit erythropoetischen stimulierungsmitteln

Country Status (12)

Country	Link
US (1)	US20080050749A1 (de)
EP (1)	EP2052256B1 (de)
JP (1)	JP5084833B2 (de)
KR (1)	KR20090034980A (de)
CN (1)	CN101506660A (de)
AT (1)	ATE544072T1 (de)
AU (1)	AU2007285733B2 (de)
BR (1)	BRPI0716614A2 (de)
CA (1)	CA2659423A1 (de)
ES (1)	ES2380498T3 (de)
MX (1)	MX2009001196A (de)
WO (1)	WO2008020043A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5753159B2 (ja) *	2009-05-05	2015-07-22	ベー．エル．アー．ハー．エム．エスゲゼルシャフトミットベシュレンクテルハフツング	内皮性機能／機能不全に関連した疾患に罹患している患者の血管作動性ホルモンに基づいた層化
EP2478367B2 (de)	2009-09-14	2018-04-04	Koninklijke Philips N.V.	Hochsensitiver Immunoassay mit grossen Partikelmarkern
TWI576091B (zh) *	2010-03-23	2017-04-01	費森尼斯醫療德國公司	造血作用刺激劑（ｅｓａ）效果之預測方法與裝置及其投予劑量之決定方法與裝置
CN103998938B (zh)	2011-10-17	2016-06-15	霍夫曼-拉罗奇有限公司	风险患者和中风原因的基于肌钙蛋白和bnp的诊断
EP2895973B1 (de) *	2012-09-14	2024-07-24	The University of Massachusetts	Verfahren und vorrichtungen zur bestimmung optimaler wirkstoffdosierungen
JP6190632B2 (ja) *	2013-06-13	2017-08-30	有限会社ネクスティア	赤血球造血刺激因子製剤の投与量決定装置
KR101531835B1 (ko) *	2013-10-16	2015-06-29	한국표준과학연구원	화학적 동위원소 치환법을 이용한 혈액 내 뇌성 나트륨 이뇨 펩타이드 질량분석법
JP7085471B2 (ja)	2015-10-05	2022-06-16	ユニバーシティオブピッツバーグ－オブザコモンウェルスシステムオブハイヤーエデュケーション	心臓バイオマーカーのインピーダンス測定による検出のための垂直配向のプラチナワイヤ・アプタセンサアレイの作成およびパラメータ評価
US11183302B1 (en) *	2015-10-12	2021-11-23	Cerner Innovation, Inc.	Clinical decision support system using phenotypic features
EP3355060A1 (de) *	2017-01-30	2018-08-01	Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts	Vorhersageverfahren von sterblichkeit aufgrund von behandlung mit erythropoese stimulierenden wirkstoffen
US12400762B2 (en)	2018-12-11	2025-08-26	Eko.Ai Pte. Ltd.	Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US11446009B2 (en)	2018-12-11	2022-09-20	Eko.Ai Pte. Ltd.	Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en)	2018-12-11	2024-03-19	Eko.Ai Pte. Ltd.	Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12001939B2 (en)	2018-12-11	2024-06-04	Eko.Ai Pte. Ltd.	Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12322100B2 (en)	2018-12-11	2025-06-03	Eko.Ai Pte. Ltd.	Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
JP7459250B2 (ja)	2019-12-23	2024-04-01	フレセニウスメディカルケアホールディングスインコーポレーテッド	赤血球造血刺激因子製剤のための接続された薬物送達システム
CN112071373A (zh) *	2020-09-02	2020-12-11	深圳晶泰科技有限公司	药物分子筛选方法及系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5744101A (en) *	1989-06-07	1998-04-28	Affymax Technologies N.V.	Photolabile nucleoside protecting groups
US5750345A (en) *	1995-10-31	1998-05-12	Evanston Hospital Corporation	Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
US6309888B1 (en) *	1998-09-04	2001-10-30	Leuven Research & Development Vzw	Detection and determination of the stages of coronary artery disease
CA2369444C (en) *	1999-04-09	2009-08-18	Ortho-Mcneil Pharmaceutical, Inc.	Pharmaceutical compositions of erythropoietin
FI20010019L (fi) *	2001-01-05	2002-07-06	Biohit Oyj	Menetelmä atrofisen diagnostisoimiseksi
US7632647B2 (en) *	2001-04-13	2009-12-15	Biosite Incorporated	Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
EP1322957B1 (de) *	2001-05-04	2009-08-12	Biosite Incorporated	Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
US20050181451A1 (en) *	2004-02-12	2005-08-18	Bates Harold M.	Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
EP1970709B1 (de) *	2007-03-06	2013-07-10	Roche Diagnostics GmbH	Verwendung von Peptiden vom Typ BNP zur Vorhersage des Dialysebedarfs

2006
- 2006-08-17 US US11/465,191 patent/US20080050749A1/en not_active Abandoned
2007
- 2007-08-15 JP JP2009524189A patent/JP5084833B2/ja active Active
- 2007-08-15 WO PCT/EP2007/058458 patent/WO2008020043A1/en not_active Ceased
- 2007-08-15 CN CNA2007800305402A patent/CN101506660A/zh active Pending
- 2007-08-15 BR BRPI0716614-1A patent/BRPI0716614A2/pt not_active IP Right Cessation
- 2007-08-15 AT AT07788437T patent/ATE544072T1/de active
- 2007-08-15 ES ES07788437T patent/ES2380498T3/es active Active
- 2007-08-15 AU AU2007285733A patent/AU2007285733B2/en not_active Expired - Fee Related
- 2007-08-15 MX MX2009001196A patent/MX2009001196A/es not_active Application Discontinuation
- 2007-08-15 KR KR1020097003154A patent/KR20090034980A/ko not_active Ceased
- 2007-08-15 EP EP07788437A patent/EP2052256B1/de active Active
- 2007-08-15 CA CA002659423A patent/CA2659423A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2008020043A1 (en)	2008-02-21
EP2052256B1 (de)	2012-02-01
JP5084833B2 (ja)	2012-11-28
JP2010501073A (ja)	2010-01-14
CN101506660A (zh)	2009-08-12
EP2052256A1 (de)	2009-04-29
BRPI0716614A2 (pt)	2013-10-08
KR20090034980A (ko)	2009-04-08
CA2659423A1 (en)	2008-02-21
ES2380498T3 (es)	2012-05-14
MX2009001196A (es)	2009-02-11
US20080050749A1 (en)	2008-02-28
AU2007285733B2 (en)	2010-10-14
AU2007285733A1 (en)	2008-02-21

Publication	Publication Date	Title
ATE544072T1 (de)	2012-02-15	Verwendung von bnp-typ-peptiden zur stratifizierung einer therapie mit erythropoetischen stimulierungsmitteln
Giallauria et al.	2018	Exercise training in patients with chronic heart failure: A new challenge for Cardiac Rehabilitation Community
Clerico et al.	2012	State of the art of BNP and NT-proBNP immunoassays: the CardioOrmoCheck study
Cove et al.	2014	Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms
Fonarow et al.	2008	Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE
Boerrigter et al.	2011	Cardiorenal actions of TRV120027, a novel ß-arrestin–biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure
Bjurman et al.	2015	High-sensitive cardiac troponin, NT-proBNP, hFABP and copeptin levels in relation to glomerular filtration rates and a medical record of cardiovascular disease
JP2026004564A (ja)	2026-01-14	心不全の治療用組成物および診断キット
RU2016112154A (ru)	2017-11-10	Способ прогнозирования риска возникновения тяжелых нежелательных сердечных явлений
DE102007022367A1 (de)	2008-11-20	Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten
Kass	2009	Pathobiology of cardiac dyssynchrony and resynchronization
ATE469353T1 (de)	2010-06-15	Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen
ATE373827T1 (de)	2007-10-15	Kombination von markern für diabetes typ 1 und 2
JP2010501073A5 (de)	2010-09-30
Kim et al.	2013	Effects of marathon running on cardiac markers and endothelin-1 in EIH athletes
DE602005001299D1 (de)	2007-07-19	Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes
Ananth et al.	2016	Does plasma copeptin level at admission predict final infarct size in ST-elevation myocardial infarction
Nordenskjöld et al.	2013	Short-and long-term individual variation in NT-proBNP levels in patients with stable coronary artery disease
Kusunose et al.	2014	Impact of vagal nerve stimulation on left atrial structure and function in a canine high-rate pacing model
Koch et al.	2006	Decreasing ratio of plasma N‐terminal pro‐B‐type natriuretic peptide and B‐type natriuretic peptide according to age
Stojadinovic et al.	2023	Acute effect of atrial fibrillation on circulating natriuretic peptides: the influence of heart rate, rhythm irregularity, and left atrial pressure overload
Pathapati et al.	2015	An open label parallel group study to assess the effects of amlodipine and cilnidipine on pulse wave velocity and augmentation pressures in mild to moderate essential hypertensive patients
Pastormerlo et al.	2015	Usefulness of high-sensitive troponin elevation after effort stress to unveil vulnerable myocardium in patients with heart failure
Şimşek et al.	2020	NT-proBNP level in stage 3-4 chronic kidney disease and mortality in long-term follow-up: HAPPY study subgroup analysis.
Climent et al.	2006	Growth hormone therapy and the heart